Citadel Advisors
MRVI icon

Citadel Advisors’s Maravai LifeSciences MRVI Stock Holding History

Citadel Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.2M Buy
1,484,319
+866,865
+140% +$2.94M ﹤0.01% 4631
2025
Q4 		$2.01M Buy
617,454
+528,600
+595% +$1.78M ﹤0.01% 5901
2025
Q3 		$255K Sell
88,854
-519,884
-85% -$1.33M ﹤0.01% 10714
2025
Q2 		$1.47M Sell
608,738
-460,059
-43% -$967K ﹤0.01% 6310
2025
Q1 		$2.36M Buy
1,068,797
+1,047,828
+4,997% +$4.14M ﹤0.01% 5215
2024
Q4 		$114K Buy
+20,969
New +$135K ﹤0.01% 11267
2024
Q3 		– Sell
-357,549
Closed -$3.09M – 14871
2024
Q2 		$2.56M Buy
357,549
+87,386
+32% +$754K ﹤0.01% 4856
2024
Q1 		$2.34M Sell
270,163
-875,519
-76% -$5.92M ﹤0.01% 5212
2023
Q4 		$7.5M Sell
1,145,682
-616,448
-35% -$3.98M ﹤0.01% 3217
2023
Q3 		$17.6M Buy
1,762,130
+1,745,774
+10,674% +$19.2M ﹤0.01% 1999
2023
Q2 		$203K Sell
16,356
-504,201
-97% -$6.81M ﹤0.01% 9858
2023
Q1 		$7.29M Buy
520,557
+24,275
+5% +$349K ﹤0.01% 3223
2022
Q4 		$7.1M Sell
496,282
-1,327,883
-73% -$20.9M ﹤0.01% 3303
2022
Q3 		$46.6M Buy
1,824,165
+1,687,956
+1,239% +$42.4M 0.01% 1121
2022
Q2 		$3.87M Sell
136,209
-298,682
-69% -$9.46M ﹤0.01% 4273
2022
Q1 		$15.3M Buy
434,891
+187,588
+76% +$6.29M ﹤0.01% 2330
2021
Q4 		$10.4M Sell
247,303
-1,070,096
-81% -$43.3M ﹤0.01% 3019
2021
Q3 		$64.7M Buy
1,317,399
+655,686
+99% +$32M 0.01% 940
2021
Q2 		$27.6M Buy
661,713
+341,175
+106% +$13.2M 0.01% 1705
2021
Q1 		$11.4M Sell
320,538
-852,991
-73% -$28.3M ﹤0.01% 2781
2020
Q4 		$32.9M Buy
+1,173,529
New +$32.7M 0.01% 1303

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's MRVI Position: Q1 2026 in Review

Citadel Advisors increased its Maravai LifeSciences (MRVI) stake by 140% in Q1 2026, buying an estimated $2.94M and bringing the position to 1,484,319 shares worth $4.2M. The position accounts for ﹤0.01% of the portfolio, ranked #4631.

Citadel Advisors first reported a position in MRVI in Q4 2020 and has held it in 21 quarters since. The position peaked at $64.7M in Q3 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Citadel Advisors held 1,484,319 shares of Maravai LifeSciences worth $4.2M as of Q1 2026.
  • Citadel Advisors bought 866,865 Maravai LifeSciences shares in Q1 2026, an estimated $2.94M.
  • Maravai LifeSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4631 holding.
  • Citadel Advisors first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Maravai LifeSciences position peaked at $64.7M in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.